The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Novo Nordisk is growing its India-based global business services to fill out vertical stacks, expand horizontal functions, ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Ozempic is a brand name for semaglutide and is a prescription medication developed by leading Danish pharmaceutical company Novo Nordisk. It functions as a glucagon-like peptide-1 (GLP-1 ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

"Semaglutide, sold by Novo Nordisk as Ozempic for type 2 diabetes and Wegovy for obesity, is part of a class of drugs known as GLP-1 receptor agonists, mimicking the hormone GLP-1 to reduce ...